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Traumatic focal defects of articular cartilage, 
those who penetrate the subchondral bone 
(osteochondral defects), heal with a repair 
tissue that degenerates in the course of the 
time. No clinically available treatment leads 
to complete and durable cartilage 
regeneration. Although the concept of gene 
therapy for cartilage damage appears 
elegant, current research indicates that an 
adaptation of gene transfer techniques to the 
problem of a circumscribed cartilage defect 
is required in order to successfully 
implement this approach. In particular, the 
localized delivery into the defect of 
therapeutic gene constructs is desirable. 
Current strategies aim at inducing 
chondrogenic pathways in the repair tissue 
that fills such defects. Among the most 
studied candidates, polypeptide growth 
factors have shown promise to enhance the 
structural quality of the repair tissue. Our 
group investigates the regulation of 
chondrogenesis in cartilage defects. We 
evaluated different therapeutic candidates in 
two- and three-dimensional systems of 
chondrogenesis in vitro. Using an 
osteochondral defect model in the rabbit 
knee we showed that nonviral 
overexpression of a human insulin-like 
growth factor I (IGF-I) and fibroblast growth 
factor 2 (FGF-2) cDNA by transplanted 
articular chondrocytes encapsulated in 
alginate spheres improved articular cartilage 
repair and accelerated the formation of the 
subchondral bone compared to control 
implants. In addition, the direct application 
of recombinant adeno-associated virus 
(rAAV) vectors to sites of cartilage damage 
allows for efficient and sustained transgene 
expression. We could further demonstrate 
that rAAV-mediated overexpression of FGF-
2 is sufficient to significantly improve the 
overall repair, filling, architecture, and cell 
morphology of osteochondral defects in 
rabbit knee joints. These data demonstrate 
that implantation of transfected articular 
chondrocytes encapsulated in alginate 
spheres into deep articular cartilage defects 
augments cartilage defect repair in vivo via 
stimulation of chondrogenesis. The data also 
provide a basis for rAAV application to sites 
of articular cartilage damage to deliver 
therapeutic agents that promote cartilage 
repair. These results suggest that therapeutic 
growth factor gene delivery using either 
encapsulated and transplanted genetically 
modified chondrocytes or direct rAAV gene 
vectors may be applicable to sites of focal 
articular cartilage damage. A better 
understanding of the basic scientific aspects 
of cartilage defect repair, together with the 
identification of additional molecular targets 
and the development of improved gene-
delivery techniques, may allow a clinical 
translation of gene therapy for cartilage 
defects.  
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